Actively Recruiting

Age: 18Years +
All Genders
ID06767605

Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)

Led by Asociación Española para el Estudio del Hígado · Updated on 2025-01-10

5000

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

AI-Summary

What this Trial Is About

This observational study aims to understand the current status of several liver diseases in Spain, including primary biliary cholangitis, autoimmune hepatitis, primary sclerosing cholangitis, and genetic cholestatic diseases. The study is sponsored by the Asociación Española para el Estudio del Hígado and focuses on collecting detailed information about these conditions within the Spanish population. Participants included in this registry have confirmed diagnoses of the liver diseases mentioned. The study collects data from 2016 through 2030, tracking how common these diseases are, the characteristics of affected patients, the development of liver-related health events, and treatments used during this period. Participants will provide information about their liver condition, which will be used to monitor disease prevalence, progression, and treatment patterns. The main outcome measured is the prevalence and features of these liver diseases by 2025. Secondary outcomes include tracking liver-related events and treatments from 2016 to 2030. Participants remain in the study through this period, contributing data to help researchers better understand these diseases in Spain.

CONDITIONS

Brief Title

Spanish Registry of Autoimmune and Cholestatic Liver Diseases (ColHai)

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients with a confirmed diagnosis for primary biliary cholangitis (PBC), autoimmune hepatitis (HAI), primary sclerosing cholangitis (PSC), or genetic cholestatic disease
Not Eligible

You will not qualify if you...

  • Refusal to sign the informed consent for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

Long-term Monitoring

Duration - Up to 14 years

Participants with autoimmune and cholestatic liver diseases are observed to monitor disease progression and treatment over time.

Trial Site Locations

Total: 1 location

1

Hospital Clinic

Barcelona, Spain

Actively Recruiting

Loading map...

Research Team

A

Asociación Española para el Estudio del Hígado Asociación Espa

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

0

Similar Trials

A Phase III Study Evaluating Elafibranor 80 mg for Long-Term...

Primary Biliary Cholangitis (PBC)

Actively Recruiting

183 locations

A Phase 2 Randomized, Double Blind, Placebo Controlled Study...

Primary Sclerosing Cholangitis (PSC)

Actively Recruiting

7 locations

A Randomised, Double-blind, Placebo-controlled, Two-part Stu...

Primary Biliary Cholangitis (PBC)

Actively Recruiting

40 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here